Mount Sinai receives $500,000 SU2C grant to identify therapeutic combinations for KRAS-mutant lung cancers

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

from The Medical News https://ift.tt/1pJo560